Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) – Outcomes Trial

In by Hannah Schaffner

Locations
Jacksonville (Headquarters), Jacksonville - LaVilla (Downtown), St. Augustine
Condition
Heart Disease

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) – Outcomes Trial

  • Hidden
  • This field is for validation purposes and should be left unchanged.

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)

clinicaltrials.gov

Eligibility

Inclusion Criteria
  • Age 18 to ≤ 85 years
  • Lp(a) ≥ 200 nmol/L during screening
  • History of ASCVD as evidenced by history of either:
    • Myocardial infarction and/or
    • Coronary revascularization with percutaneous coronary intervention with stenting AND at least 1 additional risk factor
Exclusion Criteria
  • Severe renal dysfunction
  • Active liver disease, known hepatitis, or hepatic dysfunction
  • History of hemorrhagic stroke
  • History of major bleeding disorder
  • Planned cardiac surgery or arterial revascularization
  • Severe heart failure
  • Current, recent, or planned lipoprotein apheresis
  • Previously received ribonucleic acid therapy specifically targeting Lp(a)
Back to Current Studies